Viax 50 mg (Tablet)

Unit Price: ৳ 30.00 (1 x 4: ৳ 120.00)

Strip Price: ৳ 120.00

Medicine Details

Selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)
Produces increased levels of cGMP in the corpus cavernosum upon sexual stimulation
Results in smooth muscle relaxation and increased blood flow into the penile tissues
Effective treatment for men with erectile dysfunction
Indicated in pulmonary arterial hypertension

Recommended starting dose: 50 mg
May be taken 1 hour before sexual activity
May be increased to a maximum recommended dose of 100 mg or decreased to 25 mg based on effectiveness and toleration
Maximum recommended dosing frequency is once per day

Metabolism is mediated by the cytochrome P450 (CYP) isoforms 3A4 and 2C9
Inhibitors of these isoenzymes may reduce clearance, while inducers may increase clearance
Potential interactions with CYP3A4 inhibitors, such as ketoconazole, itraconazole, erythromycin, saquinavir
Potential effects on plasma levels when co-administered with HIV protease inhibitors, alpha-blockers, and endothelin receptor antagonist bosentan

Body as a whole: face edema, photosensitivity reaction, shock, asthenia, pain
Cardiovascular: angina pectoris, AV block, migraine, syncope
Digestive: vomiting, glossitis, colitis, dysphagia
Hemic and Lymphatic: anemia, leukopenia
Metabolic and Nutritional: thirst, edema, gout, unstable diabetes
Musculoskeletal: arthritis, arthrosis, myalgia
Nervous: ataxia, hypertonia, neuralgia, neuropathy
Respiratory: asthma, dyspnea, laryngitis
Skin and Appendages: urticaria, herpes simplex, pruritus
Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis
Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence

Caution advised when co-administered with alpha-blockers
Considerations for patients with hemodynamic instability, bleeding disorders, active peptic ulceration, anatomical deformation of the penis
Potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease
Sensitivity to the actions of vasodilators including Viax in specific patient groups
Risk of prolonged erection greater than 4 hours and priapism
Unknown safety and efficacy in certain patient groups

Adverse events similar to lower doses, but with increased incidence rates and severities
Standard supportive measures should be adopted in cases of overdose
Renal dialysis is not expected to accelerate clearance